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Abstract
Hemolytic disease of the fetus and newborn (HDFN) also called as “erythro-
blastosis fetalis” is characterized by the increased rate of red blood cells (RBCs)
destruction. Hemolysis should always be investigated even if the anemia is mild and
apparently trivial. The principle clues which suggest hemolytic anemia includes:
increased number of reticulocytes and/or circulating nucleated RBCs, unconjugated
hyperbilirubinemia, a positive direct antiglobulin test and characteristic changes in
red cells in the blood films. Based on etiology, hemolysis in newborn can be immune
or non-immune mediated. The immune-mediated hemolysis due to blood group
incompatibility between the mother and the fetus is the main cause of HDFN.
Keywords: hemolysis, blood groups
1. Introduction
Hemolytic disease of the fetus and newborn (HDFN) also called as “erythro-
blastosis fetalis” is characterized by the increased rate of red blood cell (RBC)
destruction. Hemolysis should always be investigated even if anemia is mild and
apparently trivial. The principle clues which suggest hemolytic anemia include
increased number of reticulocytes and/or circulating nucleated RBCs, unconjugated
hyperbilirubinemia, a positive direct antiglobulin test, and characteristic changes in
red cells in the blood films [1, 2]. Based on etiology, hemolysis in newborn can be
immune or nonimmune mediated. The nonimmune causes include α-thalassemia,
RBC membrane, or enzyme defects [1]. The immune-mediated hemolysis due to
blood group incompatibility between the mother and the fetus is the main cause of
HDFN. Immune-mediated hemolysis of fetal red cells, due to blood group incom-
patibility, occurs when there is transplacental passage of maternal antibody active
against paternal red cell antigen of the infant [2–4]. Both naturally occurring and
immune antibodies are implicated leading to a spectrum of clinical sequela, ranging
from anemia and hyperbilirubinemia to fetal hydrops, kernicterus, and death [3, 4].
Although more than 60 different RBC antigens are capable of eliciting an antibody
response, significant morbidity is associated primarily with D antigen of Rh group
[2]. The prevalence of red cell antibodies other than anti-D with the potency to
induce HDFN is about 1 in 500 pregnancies [5–7].
2. History
The royal family of England was not spared from the features of HDFN. Henry
VIII’s first wife, Katherine of Aragon, conceived six times, among which five died in
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the perinatal period due to features presumed to be of HDFN [8]. The well-
documented description of HDFN was made in 1609 by the midwife in the French
literature. The case was a twin gestation in which the first fetus was stillborn and
the second twin developed jaundice and succumbed soon after birth [9]. In 1940,
Rh blood group system was described by Landsteiner and Wiener, and in 1941
Levine et al. determined that D antigen in Rh system is the agent for HDFN [10, 11].
The main cause of sensitization though was stated by Levine in 1940 but was
described in detail by Keenan and Pearse in 1963 [12]. In 1961 Liley, for the first
time, described intrauterine transfusion into the abdominal cavity of the fetus as a
preventive measure for the disease [13]. Exchange transfusion, introduced by
Wallerstein, and induced premature delivery are other treatment options employed
for the management of HDFN [14, 15]. Until 1960, HDFN due to rhesus blood
group system was considered the major contributor to the perinatal mortality rates.
In 1961, Finn et al. defined the administration of anti-D Ig in the prevention of Rh
sensitization and later in 1967 along with two German scientists Schneider and
Preisler proved that anti-D is not useful in already sensitized mothers [16, 17]. This
was a major breakthrough in prevention of sensitization with administration of
400 μg of human anti-D globulin within 72 h after delivery. Since 1971, the WHO
recommends empirical use of anti-D Ig following any sensitizing event including
after delivery of Rh-positive newborn and for abortions.
3. Blood group antigens and antibodies
An antigen is any substance which, when introduced into the body of an immu-
nocompetent individual, stimulates the immune system by production of an anti-
body by interacting with the immunoglobulin receptor of B cell. Each red cell
membrane is a bi-phospholipid layer containing millions of antigen on its surface
[18]. The blood group antigens are either protein or carbohydrate structures present
on the red cell membrane. An individual’s blood group is determined by the antigen
expressed on the surface of red cell membrane. The carbohydrate antigens are
expressed as it is, while the protein antigens stretch in the bi-phospholipid layer by
transmembrane proteins [19].
Antibodies are recognition proteins found in the serum and other body fluids of
vertebrates that react specifically with the antigens that induce their formation.
Antibodies belong to a family of globular proteins called immunoglobulins. The
terms antibody and immunoglobulins are used synonymously. They are produced
by the lymphocyte-plasma cell system. Antibodies bind antigen, fix complement,
facilitate phagocytosis, and neutralize toxic substances in the circulation [18]. IgG,
IgM, and IgA are the most significant from the point of view of transfusion medi-
cine. Most clinically significant antibodies are IgG type, reacting at body tempera-
ture (37°C) with the antigens, and cause significant in transfusion reactions as they
are a class of antibodies produced in response to nonself-antigens on the blood
products. IgM antibodies are mostly naturally occurring antibodies [19].
4. Alloimmunization during pregnancy
Alloimmunization can be caused due to pregnancy, blood transfusion, or tissue/
organ transplantation or grafting, due to genetic difference between the individuals
[20]. On exposure to a foreign red cell antigen, the immune system is activated
which is mediated by lymphocytes. The first step involved is recognition of the
antigen by T cell. The recipient’s helper T cell interacts with the MHC class II
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molecule expressed on the donor red cells. Following the initial interaction, T cells
trigger a second signal for the B lymphocytes, in order to stimulate humoral
immune response [20, 21]. Initially, IgM class of antibody is produced in primary
response to an antigen and is formed as early as 4 weeks to 3 months period.
However, there is a switch of IgM to IgG class during the secondary response [20].
The secondary response is more rapid, potent, and specific than the primary.
Placenta is a natural barrier present between mother and fetus. Only IgG anti-
bodies can cross the placenta. The transfer is mediated by the neonatal Fc receptors
(FcRn) [6]. The immunoglobulin is bound and transported by FcRn of syncytiotro-
phoblast which also protects IgG molecule from normal serum protein catabolism.
In the first trimester, there is relatively less transfer; however, it subsequently
increases exponentially in the second and third trimester. Mean concentration in the
fetus at the 24th week of pregnancy is 1.8 g/dL. The IgG antibody levels are higher
in the fetus than in the mother toward the term [22]. Of the four subclasses of IgG
antibody, IgG3 and IgG1 are more efficient in RBC hemolysis than IgG2 and IgG4,
though all the four classes are efficiently transferred across the placenta [23].
4.1 Sensitizing events
Transplacental feto-maternal hemorrhage occurs in over 75% of pregnancies.
The average volume of fetal blood in the maternal circulation following delivery is
less than 1 mL in 96% of pregnancies [24]. As the pregnancy progresses, the
possibility of feto-maternal hemorrhage increases, 3% in first trimester, 12% in the
second, 45% in the third, and 64% at the time of delivery as shown by Bowman
[22]. It has been reported that as little as 0.1 mL of antigen-positive blood is
sufficient to cause sensitization in an antigen-negative mother [23]. Feto-maternal
hemorrhage can occur due to various antenatal and postnatal events in Table 1.
5. Pathophysiology for HDFN
HDFN is the destruction of fetal and newborn red cells by maternal alloanti-
bodies specific for the inherited paternal red cell alloantigens. While IgM is usually
detected in the maternal circulation during primary response, IgG is found during
secondary response, which appears about 5–15 weeks after feto-maternal hemor-
rhage. Because exposure to fetal red cells and resulting maternal alloimmunization
typically occurs late during pregnancy and at delivery, and IgM does not cross the
placenta, the fetus and newborn of the first pregnancy are rarely affected. Re-
Antepartum Intrapartum Postpartum
Early pregnancy
Abortion (spontaneous or induced)
Ectopic pregnancy
Late pregnancy
Placetal abruption
Abodominal trauma
Obstetric procedures
Amniocentesis
Chorionic villus sampling
External cephalic version
Fetal blood sampling
Caesarean section
Manual removal of placenta
Blood transfusion
Table 1.
Sensitizing events for feto-maternal haemorrhage [24].
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exposure to red cell antigen during subsequent pregnancies produces IgG in suffi-
cient concentration [4].
The sensitized fetal red cells by maternal IgG antibody are unable to continue in
the circulation, and these red cells are destroyed by the fetal spleen resulting in
anemia. Compensatory erythropoiesis is induced by fetal anemia initially [25]. The
exception to this rule is antibodies Kell blood group system and MNS system which
cause destruction of erythroid progenitor cells, causing early anemia without eryth-
roblastosis [26, 27]. Hyperdynamic circulation tries to compensate anemia in the
fetus, which subsequently leads to cardiomegaly, and finally fetal hydrops develops
[25]. Due to hemolysis of the fetal cell, there is rise in the bilirubin level in the fetus.
In utero, the bilirubin is excreted by the mother, when it is transported across the
placenta, so the severity of hyperbilirubinemia is not observed. After delivery, the
hemolysis continues, but the comparatively immature liver of the neonate is unable
to sufficiently conjugate the excess of bilirubin. This subsequently leads to severe
hyperbilirubinemia and, when left untreated, could result in “kernicterus” [4, 25, 28].
6. Clinical relevance of different red cell alloantibody specificities
The risk of developing severe HDFN depends on several factors, including Ig
class, specificity of the red cell alloantibodies, and level of expression of the involved
blood group antigen on the fetal red cells and other tissues as shown in Table 2 [25].
6.1 Rh blood group system
Rh system is more complex than the single antigen system. Five principal Rh
antigens D, C, c, E, and e are responsible for the majority of clinically significant
antibodies, but over 50 different Rh antigens have been described [29].
Antibody
specificities
Risk to develop HDFN in antigen-positive children and clinical course of
disease
ABO Low risk for disease, in general mild, incidentally severe
Rh
D
c
E
Other Rh antigens
High risk for disease, often (very) severe, otherwise mild
High risk for disease, (very) severe or mild
Medium risk for disease, sometimes severe, but mostly mild
Medium risk for disease, incidentally severe, but mostly mild
Kell
K
Other Kell antigens
High risk for disease, (very) severe or mild
Medium risk mild to severe disease
Duffy
Fya/Fyb
Medium risk for disease, mostly mild
Kidd
Jka/Jkb
Low risk for disease, only mild
MNS
M, N, S, s
Other antigens
Low risk for disease, mostly mild disease, very rarely severe
Low risk for disease, mostly mild disease, very rarely severe
I, Le, P1, Lu, Yt No risk, because of very low expression of these antigens by fetal cells
Other antigen
systems
Very low risk, very rarely severe disease can develop
Table 2.
Red cell antibody specificities in reference to induce HDFN [25].
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D is by far the most immunogenic of all the Rh antigens. Hence, it is common in
clinical practice to equate D with Rh and to use the terms Rh-positive and Rh-
negative to describe “D-positive” and “D-negative” [30].
Rh antibodies implicated in HDFN are:
• Severe HDFN—anti-D and anti-c [31, 32]
• Mild disease—anti-C, anti-E, and anti-e [33–37]
6.1.1 D antigen and antibodies
The D antigen carried by the RhD proteins is the most immunogenic and most
important blood group antigen leading to HDFN. There is no antithetical antigen to
D [4]. The first blood group antigen to be associated with HDFN was described by
Levine et al. in 1945 [9]. About 15% of Western world and 8% of blacks are D-
negative [38, 39]. If a unit of D-positive blood is transfused to a D-negative recipi-
ent, the recipient will form anti-D in around 90% of cases, and subsequently D-
positive red cells cannot be given safely to these patients [29].
Sensitization to D antigen can occur in reaction to less than 0.1 mL of fetal blood,
resulting in formation of anti-D in the maternal circulation [22]. Before 1945, more
than 50% of all fetus with HDFN died of kernicterus or hydrops fetalis, and anti-D
was the most common associated [9, 40]. With improvement of treatment, in
industrialized countries the mortality reduced to 2–3%. But anti-D is still among the
most frequently detected antibodies in sensitized pregnancies.
Very early, it was understood that, if the D-negative mother was carrying an
ABO-compatible D-positive fetus, her risk of Rh immunization was 16%. If the D-
positive fetus was ABO-incompatible, the risk was only 2%. So, the overall risk of
Rh immunization is 13.2% [9].
Not only in Rh-negative pregnancies does anti-D causes HDFN, but also case
reports have been reported for HDFN due to anti-D in Rh-positive pregnancies [41–
43]. These are mostly due to the Rh variants: weak D, Du, and partial D described
by molecular analysis [30].
6.1.1.1 Blocked D phenomenon
The blocking of D antigen sites by IgG anti-D in severe cases of HDFN is a rare
phenomenon explained byWiener in 1944 [44]. Only a handful of case reports have
been described in the literature [45–48]. The coating of maternal anti-D IgG on the
D-positive red blood cells (RBCs) of the newborn gives false-negative D typing,
when IgM typing reagent anti-D is used. This phenomenon is not limited to anti-D,
but is seen with other blood groups [49]. BCSH describes guideline for resolving
such cases [50].
6.1.1.2 Rh immunoglobulin prophylaxis
Rh immunoglobulin (RhIG) prophylaxis for D-negative pregnant women is
now the international cornerstone for prevention of maternal alloimmunization to
the D antigen and subsequent HDFN [50, 51].
During the mid-1960s, experiments were carried out in various parts of the
world for preventing HDFN due to anti-D. Clinical trials showed that, when
unimmunized mothers who have delivered D-positive infants, were given RhIG
prevented the development of anti-D in the mother. RhIG is obtained from the
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human plasma. RhIG has to be given within 72 h after delivery of a D-positive
infant. Since 1968, RhIG is licensed for prevention of HDFN [9, 21, 22].
The effectiveness of RhIG in order to prevent isoimmunization is determined by
adequate dosage and should be administered before initiation of Rh
isoimmunization [50].
There are various mechanisms describing the role of RhIG in preventing HDFN.
Though antigenic epitopes are not fully masked by anti-D, they are still available for
immune system recognition. But anti-D is be able to destroy RBCs without trigger-
ing the adaptive immune response, by inhibition of FcgammaRIIB signaling in B
cells which is called as antibody-mediated immune suppression (AMIS) [21, 52, 53].
The T-cell response and memory may still be intact.
Various studies were carried out in the 1970s after systemic implementation
of systemic anti-D prophylaxis, which showed reduction in HDFN from
16 to 0.3% [54].
The standard guidelines recommend to administer RhIG as soon after delivery as
the infant is determined to be D-positive or latest within 72 hours after delivery or
after any antenatal procedure, where the risk of feto-maternal hemorrhage is high
as shown in Table 3 [50]. It has been shown experimentally that at least partial
protection is afforded by giving RhIG up to 13 days after exposure to D-positive
RBCs. Rh prophylaxis therefore is recommended up to 28 days after delivery, with
the understanding, however, that the longer the prophylaxis after delivery is
delayed, the less likely it is to be effective [28, 55].
In 2014, Cohen et al. described a case report on severe HDFN caused due to
passive transfer of anti-D from maternal RhIG [56].
6.1.2 Other Rh system antibodies other than anti-D
With widespread use of RhD immunoglobulin, the focus has shifted to the non-
RhD antibodies causing isoimmunization. Other Rh antigens include C, c, E, and e
antigens. DCe is the most common haplotype in Caucasians (42%), Native Ameri-
cans (44%), and Asians (70%) [57].
6.1.3 Anti-c
Anti-c is usually described as the next most common cause of severe HDFN after
anti-D. Various case reports have been reported, stating that anti-c
isoimmunization can cause HDFN from mild to severe degree [31, 32, 58, 59]. A
titer of more than 1:32 is associated with hydrops fetalis as described by David et al.
[58]. BCSH guidelines state that women with anti-c should be retested following the
same protocol as for anti-D [50]. Quantification of the antibodies is expressed in
terms of IU/mL. Mothers with antibody concentration of less than 7.5 IU/mL are
advised to continue the pregnancy, while 7.5–20 IU/mL are at a risk of moderate
HDFN and more than 20 IU/mL, severe HDFN. It should be kept in mind that anti-c
causes delayed anemia in neonate [50].
6.1.4 Anti-D + anti-C or anti-G
D-positive or C-positive RBCs have G antigen which was first described by Allen
and Tippett in 1958 [60]. The G antigen is co-distributed either with C or D antigen
which causes anti-G to appear serologically as anti-C plus anti-D [60]. During
pregnancy, it is apparently important to distinguish between anti-D, anti-G, and
anti-D + C. As the pregnancies without anti-D are candidates for the administration
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of RhIG. The administration of RhIG can be avoided if anti-D has already devel-
oped. D-negative mothers with anti-G are potential candidates to receive RhIG in
order to prevent formation of anti-D. It also avoids the associated social
or medicolegal complications [61]. The clinical significance of anti-G alone in
causing mild to severe HDFN still remains controversial [62]. The isolation of
anti-G by double adsorption and elution is a tedious and relatively complex
procedure [63]. The technique to distinguish anti-D + C from anti-G is recently
described by Fatima et al. [64].
6.1.5 Anti-C, anti-E, anti-e, and others
Anti-RhC, anti-RhE, and anti-Rhe antibodies are of Rhesus family and
usually occur in low titer in conjunction with anti-RhD antibody. Their presence
can be additive to the hemolytic effect of the anti-RhD on the fetus [65, 66].
Various reports have been published on pregnancies alloimmunized only to
RhE [36, 37].
Hardy and Napier in their review of red blood cell antibodies among Rh-positive
women in South and Mid Wales over a 30-year period (1948–1978) described two
infants with hemolytic disease caused by anti-C [67].
Anti-e is usually a very rare cause of HDN; the disease is usually mild [68].
In addition to the above antibodies, there are many other antibodies belonging to
Rh family which are associated with HDFN [35, 69, 70].
Recommendations Strength of
recommendation
Quality of
evidence
Postpartum prophylaxis
• Anti-D 120–300 μg within 72 h of delivery
• Anti-D up to 28 days after delivery
• Routine FMH testing after delivery
A
B
C
I
II
Insufficient
Antepartum prophylaxis
• Anti-D 300 μg at 28 weeks
• Repeat antibody screening at 28 weeks
• Routine paternal testing
• Anti-D for “weak D” (e.g., Du)
• Repeat anti-D at 40 weeks
A
C
C
D
D
I
III
III
III
III
Early pregnancy loss and termination
• Anti-D 120–300 μg after spontaneous/induced
abortion
• Antibody screening prior to anti-D after abortion
• Ectopic pregnancy: 120–300 μg Rh immune
globulin
•Molar pregnancy: 120–300 μg Rh immune globulin
B
B
B
B
II-3
III
III
III
Invasive fetal procedures
• Amniocentesis: 300 μg Rh immune globulin
• CVS: 120–300 μg Rh immune globulin
• Cordocentesis: 300 μg Rh immune globulin
B
B
B
II-3
II
II-3
APH, abdominal trauma, ECV, FMH
• Quantitative FMH testing
• Anti-D 120–300 μg following placental trauma
B
B
III
III
Consent
• Informed consent prior to administration of anti-D
C III
Table 3.
Anti-D prophylaxis and quality of evidence available [50, 54, 55].
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6.2 Kell blood group system
A mnemonic goes “Duffy dies, Kell kills, and Lewy lives” [71]. Kell blood group
system is clinically significant in terms of transfusion medicine and perinatology. It
relates to the polymorphic nature of the Kell protein. It is also associated with the
Kx and Gerbich blood group systems. K is formed in fetuses of 10–11 weeks and k at
6–7 weeks of gestation [72, 73].
Alloimmunization to Kell blood group antigens is due to previous blood trans-
fusion or feto-maternal hemorrhage induced during pregnancy [73]. Kell
alloimmunization is the second major cause for fetal hemolytic anemia, with a
reported and still increasing incidence in a large US series of 3.2 in 1000 and
affecting 1 in 10,000 neonates [74].
6.2.1 Anti-K
Anti-K antibodies differ from the other blood group system antibodies that
cause HDFN in suppressing fetal non-hemoglobinized erythropoiesis, causing
severe anemia and often death of the fetus. The high bilirubin level is not a charac-
teristic feature as the precursor cells are destroyed. Amniocentesis therefore does
not give an indication of the severity of the disease. Successful management of RBC-
alloimmunized pregnancies depends on early detection of fetal anemia and timely
intervention by intrauterine blood transfusions [75–77].
Perinatal survival in severe Kell alloimmunization was only 58% as recorded
after implementation of routine screening nationwide in the Netherlands from 1988
to 2005 [75].
In some countries it is usually practiced to give K-negative red cells for girls and
women of childbearing age group [78].
6.3 Detection of feto-maternal hemorrhage (FMH)
6.3.1 KB test
As mentioned earlier, feto-maternal hemorrhage increases as the pregnancy
progresses: 3% in the first trimester, 12% in the second, 45% in the third, and 64%
at the time of delivery [22]. These fetal cells which have crossed the placenta can be
detected by acid elution method of differential staining described by Kleinhauer
and Betke in 1960 [79].
6.3.2 α-Fetoprotein (α-FP)
α-FP is an analogue of albumin [6]. Seppala and Ruoslahti in 1972 and Caballero
et al. in 1977 used α-FP as an index of transplacental hemorrhage (TPH) [80, 81].
6.3.3 Others
Apart from quantification, the serological methods for detecting transplacental
hemorrhage are also available. This includes rosetting test and flow cytometry.
Rosetting test is not sensitive, as it needs at least 15 mL or more of fetal cells to be
present in the maternal circulation to give a positive result [19].
Flow cytometry is the most sensitive test technique in detecting the amount of
TPH [19, 82].
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The other surrogate markers of FMH include enzyme-linked antiglobulin test
(ELAT), placental alkaline phosphatase (PLAP), polymerase chain reaction (PCR),
and fluorescence in situ hybridization (FISH).
6.4 Antibody screening
It had been a common practice to screen the sera of all Rh(D)-negative pregnant
women for Rh antibodies. Later, when it was found that Rh(D)-positive women
could also have babies with HDFN due to Rh antibodies (other than anti-D) and
non-Rh antibodies, it was suggested that sera from all pregnant women should be
screened for antibodies [6, 25, 83].
6.4.1 Screening methods
The indirect antiglobulin test (IAT) using reagent red cells suspended in low
ionic strength saline (LISS) is the most suitable method for detection of clinically
significant red cell antibodies [84]. Column agglutination methods, liquid-phase
tube tests, and solid-phase methods have also been found to be suitable [50].
6.4.2 Guidelines for antenatal antibody screening
Various countries have developed guidelines for screening of antenatal cases.
Scientific Section Coordinating Committee of the American Association of Blood
Banks (AABB) has issued guidelines (not AABB standards) for serological testing of
pregnant women [85]. Table 4 shows the recommendations for prenatal testing.
The BCSH Task Force has also laid guidelines in 2007 for blood grouping and
antibody testing in pregnancy as follows [50]:
Testing and condition Timing
ABO
First pregnancy
Subsequent pregnancies
Other
Initial visit
Initial visit
For pretransfusion testing
Rh (test for weak D optional)
First pregnancy
Subsequent pregnancies
Other
Initial visit and at 26–28 weeks’ gestation
Initial visit
For pretransfusion testing
Unexpected antibodies
All pregnancies
D pregnancies
D+ pregnancies
Other
Initial visit
Before Rh Ig therapy (optional)
Third trimester if transfused or history of unexpected
antibodies
For pretransfusion testing
Antibody identification
Unexpected antibodies present
Confirmatory testing
Upon initial detection
At time of titration
Antibody titration
Rh antibodies
Other potentially significant
antibodies
Upon initial detection
Repeat at 18–20 weeks’ gestation
Repeat at 2- to 4-week intervals if below critical titer [16–32]
As above, with discussion with obstetrician
Table 4.
AABB recommendations for prenatal testing [85].
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• “All pregnant women should have samples taken early in pregnancy, ideally at
10–16 weeks gestation, for ABO and D typing and for screening for the
presence of red cell alloantibodies.”
• “All pregnant women, whether D-positive or -negative should have a further
blood sample taken at 28 weeks gestation for rechecking the ABO and D group
and further screening for red cell alloantibodies.”
• “No further routine blood grouping or antibody screening is necessary after
28 weeks of gestation.”
Australian and New Zealand guidelines have been adapted from AABB recom-
mendations for pregnant women [85, 86]. However, repeat testing of RhD-negative
women only at 28 weeks, prior to administering RhIG, is becoming the accepted
protocol in most Australian centers, eliminating the norm of antibody screening
at 34–36 weeks. In New Zealand, in the absence of routine antenatal prophylaxis,
the normal practice is to test RhD-negative women at 28 and 36 weeks of
gestation [86].
The latest guidelines for alloimmunized pregnancy framed and followed in Japan
since 2014 are as follows [87]:
• “Identify the antibody when a screening test, such as the indirect Coombs test,
suggests the presence of an atypical antibody against red blood cells.”
• “Assess the titer of the antibody if the antibody belongs to IgG class that may
cause hemolysis in the fetus.”
• “Monitor the fetal well-being, paying special attention to anemia and hydrops,
in women with an elevated titer of an IgG antibody that may cause hemolysis
in the fetus.”
• “Be prepared to administer un-crossmatched packed red blood cells compatible
with an ABO blood type if the pregnant woman develops unexpected massive
bleeding.”
6.5 Methods of red cell antibody detection and identification
Antibody detection plays a critical role in detection and monitoring of antenatal
cases who are at risk of delivering neonates with HFDN [88].
Most of the clinically significant antibodies are IgG in nature, which are non-
agglutinating or incomplete antibodies, so they can only sensitize red cells but
cannot produce agglutination. Coombs et al. in 1945 described “antiglobulin test”
for detection of these non-agglutinating antibodies [89].
The presence of red cell antibodies in patient’s serum or plasma and an
in vitro reaction between red cell detection are demonstrated by indirect antiglob-
ulin test [89]. Indirect antiglobulin test is considered to be the most effective and
reliable method for detection of clinically significant antibodies [84]. Several
studies have shown that the column agglutination test is better than tube and
solid-phase tests.
The gel technique has shown sensitivity as compared with conventional test
tube (CTT) methods (93.5–100% for CAT vs. 50% for CTT) [90–93]. The
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sensitivity of SPRCA has been found to be superior to CTT and comparable with
that of CAT [94].
6.6 Quantification of antibody in the serum
Titration is a semiquantitative method to estimate the strength and concentra-
tion of antibodies present in a serum sample [95]. Titers give only rough estimates
of the amount of antibody bound to the target RBCs and do not measure the amount
of antibody remaining free in solution at the endpoint of agglutination [96]:
• The critical titer for anti-D (the level below which HDFN and hydrops fetalis are
considered unlikely is usually 16 or 32 in antihuman globulin (AHG) phase).
These titer criteria apply to anti-D, to other Rh antibodies, and generally to other
clinically significant antibodies, with anti-K as possible exception.
• A critical titer of 8 is considered for anti-K.
• As long as the titer is 8 or lower (except anti-K), the pregnancy can be followed
up every 4–6 weeks until delivery.
• A difference of two dilutions or a score of 10 is considered a significant
change [4].
• A score may also be assigned, based on the strength of reactivity.
• Each reaction is given a value, and score is determined by adding up individual
values.
• Most hospitals have set up their critical antibody titer, at which amniocentesis
is recommended.
There are various methods of performing the titration, conventional tube test
(CTT), or by gel microcolumn assay (GMA) [95, 97]. A study by Thakur et al.
showed that gel technique is more sensitive for antibody detection. It does not show
a linear correlation with tube titers in predicting the outcome in RhD-sensitized
women, while Rachel et al. suggested that GMA gives comparable results to the CTT
in titrating alloantibodies to Rh and Kell antigens [95, 97].
6.7 Amniotic fluid analysis
Amniocentesis is helpful in determining the overall condition of the fetus and is
mostly indicated when the clinically significant maternal antibody titer is 1:32 or
greater in the fourth or fifth month of pregnancy [4, 19, 98]. If there is a history of a
previous pregnancy complicated by HDN, amniocentesis is indicated regardless of
the present maternal serum antibody titer.
In 1961, Liley developed a chart depicting change in amniotic fluid bilirubin
levels (delta OD450) with period of gestation, with three zones delineating the
severity of rhesus disease [99]. The chart is useful only after the 27th week of
gestation. Currently, cordocentesis is the only reliable means of assessing the
fetal condition accurately prior to 27 weeks. In 1993, Queenan proposed a chart
showing delta OD450 from 14 to 40 weeks, with four zones to guide
management [100].
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6.8 Other methods for assessing the severity of HDFN
6.8.1 Ultrasound
Some of the pathophysiological changes in the fetus due to anemia could be
shown using ultrasound [6]. Real-time sonography accurately predicted the clinical
course in 86% of the cases, with no false-positive predictions [101].
With recent advances, Doppler ultrasonography, which measures fetal hemo-
dynamics, has been used, and it gives better results in predicting fetal anemia as
early as the 18th week. The Doppler assessment of peak systolic velocity in the
middle cerebral artery (MCA-PSV) is done [102]. It is hypothesized that faster rate
of blood flow indicates a more severely anemic fetus, with severe anemia being an
indicator of fetal hydrops.
6.8.2 Fetoscopy, percutaneous umbilical blood sampling (cordocentesis), and chorionic
villus biopsy
Fetoscopy is a technique in which the second-trimester fetus can be visualized
directly and fetal blood (or other tissues) can be sampled through an endoscope
introduced transabdominally into the amniotic cavity. The technique is only reliably
successful at 16 weeks of gestation and later. Fetoscopy carries a mortality rate of
5% as compared to a 1–2% mortality rate after midtrimester amniocentesis. The
fetal blood can be tested for blood type, DAT, hemoglobin, and hematocrit [96].
MacKenzie and coworkers suggested that the technique would be of benefit in cases
where the father of the baby is known to be heterozygous for the offending blood
group antigen in the following situations:
1. Patients with a history of previous babies having severe HDFN.
2. Patients with high-titer anti-D (e.g., in excess of 20 IU/mL) during the first
20 weeks of pregnancy.
6.8.3 Prenatal determination of fetal blood groups
The father’s probable genotype is predicted. If the father is thought to be homo-
zygous, the baby is assumed to possess the putative antigen. If the father is hetero-
zygous, there is a 50% chance that the baby is antigen-positive [6, 96]. Antenatal
genotyping of the fetus is now in widespread use as an aid to the clinical manage-
ment in cases where there is a possibility of occurancy of hemolytic disease of the
newborn [121]. Molecular genotyping is a major clinical application which has led to
the determination basis of blood group antigens expressed, most of which have
been defined at the level of the gene. All assays used are dependent on the poly-
merase chain reaction amplification of fetal DNA derived from.
6.8.4 In vitro predictive tests utilizing functional cellular assays
They are based on the in vivo mechanisms of RBC immune destruction. The
interactions with the monocytes are measured by recording RBC adherence/
phagocytosis by a monocyte monolayer assay (MMA), antibody-dependent
cellular cytotoxicity (ADCC) using 51Cr-labeled RBCs, or a chemiluminescence
test (CL) using luminol. These tests are not very accurate in predicting the severity
of HDFN [6, 96].
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6.9 Antenatal treatment of hemolytic disease
6.9.1 Plasma exchange in mother
A known therapeutic approach for red cell alloimmunization is plasmapheresis
in the mother in order to reduce maternal antibody titer [103]. In the current era,
plasma exchange treatment appears to be useful in cases of HDFN developed early
in pregnancy (before 20 weeks). The American Society for Apheresis in 2013
proposed that plasmapheresis should be considered early in pregnancy (from the
7th to the 20th week) and continued until IUT can be safely administered (approx.
20 weeks of gestation) [104].
6.9.2 Absorption of alloantibodies onto red cells
Plasma containing the antibodies is drawn from the patient, the antibodies are
absorbed using appropriate cells, and then plasma is returned to the patient [19].
During the 1980s, this procedure was attempted by Robinson and Yoshida et al. for
an Rh-immunized woman [105, 106].
6.9.3 Intravenous immunoglobulin given to the mother
The use of intravenous immunoglobulin (IVIG) to the mother is one of the
alternative strategies developed in past 20 years for the management of severely
alloimmunized pregnancies [107]. The mechanism by which IVIG might act is
saturation of FcRn, thereby inhibiting placental transfer of anti-D to the fetus as
shown by Morgan et al. in 1991 [108]. A single course of 2 g/kg over 5 days or
repeated weekly injections of 1 g/kg have been tried in conjunction with plasma
exchange or with intravascular transfusion of the fetus [109]. There is no other
description of the dosing during the antenatal period.
6.9.4 IVIG given to the fetus
IVIG given to the fetus did not show any beneficial effect [19].
6.9.5 Intrauterine transfusion
In 1970, Pontuch stated five strategies as a preventive measure for HDFN, which
are valid to this day [110]:
1. “Prevention of leakage of fetal erythrocytes into maternal circulation and
antibodies in the opposite direction”
2. “Blockage of antibody production in the maternal circulation”
3. “Prevention of sensitization of maternal erythrocytes with fetal erythrocytes”
4.“Prevention of Rh sensitization by anti-D administration”
5. “Intrauterine transfusion in pregnancy”
One of the oldest methods, introduced by Sir William Liley, is intraperitoneal
fetal blood transfusion into the abdominal cavity of the fetus under X-ray guidance
[111]. The donor cells were absorbed into the fetal circulation via the
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subdiaphragmatic lymphatics and thoracic duct, which, in conjunction with the use
of amniotic fluid analysis for bilirubin levels, markedly improved the management
of Rh-sensitized pregnancies.
From the time of its initiation, IUT has come a long way. Initially, it was
intraperitoneal, but in 1981, Rodeck et al. described intravascular transfusion by
using the umbilical cord and fetoscope [112].
The formula for calculation of blood volume for IUT is shown below [113]:
V ¼
Desired PCV–Fetal PCVð Þ  Fetoplacental BV
Donor PCV–Desired PCVð Þ
:
Red cell prerequisites for IUT as described by BCSH guidelines are as follows
[113]:
• “Group O (low titre haemolysin) or ABO identical with the fetus (if known)
and RhD negative”
• “IAT-cross-match compatible with maternal serum and negative for the
relevant antigens determined by maternal antibody status”
• “Less than 5 days old and in citrate phosphate dextrose (CPD) anticoagulant”
• “CMV seronegative and irradiated”
• “Should have a haematocrit (packed cell volume, PCV) of up to but not more
than 0.75”
• “Not be transfused straight from 4°C storage”
• “The rate of transfusion should be 5–10 mL/min”
The target of a single IUT is to reach Hct 48–55% in non-hydropic fetuses [103].
6.9.6 Induction of GvHD
Immunomodulatory effect due to transfusion to the fetus by IUT due to the HLA
group of the donor causes GvHD [19].
6.9.7 Premature delivery
Premature induction of labor may be considered, as after the birth of the infant,
placental transfer of antibody ceases [6, 28].
6.10 Postnatal intervention for hemolytic disease
6.10.1 Exchange transfusion
The main purposes of exchange transfusion in HDFN are as follows [28, 114]:
1.With sedimented red cells, it can raise the hematocrit without increasing the
blood volume of a severely affected erythroblastotic newborn infant in the first
minutes of life.
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2. It can remove antibody-coated cells from the circulation of newborn before
they hemolyze and produce bilirubin.
3. It can remove bilirubin in the circulating plasma and some from extravascular
areas, so that its concentration can be kept below levels which are generally
considered to be toxic to tissues—particularly central nervous system tissues.
The method was introduced by Diamond (1947). Blood was withdrawn and
injected, intermittently, through a plastic catheter passed up the umbilical vein [110].
For HDFN double-volume exchange is mostly preferred, where approximately
85% of the blood volume is replaced and will cause an approximate reduction of
50% in pre-exchange bilirubin level [114–116]. The American Academy of Pediat-
rics (AAP) has published guidelines, recommending not to initiate early ET, such as
within the first 12 h of birth. The bilirubin threshold for the start of ET depends on
the gestational age at which the baby is born [117].
Components used in exchange transfusion.
Red cells for exchange transfusion should meet the following BCSH criteria
[113, 118]:
• “Group O or ABO compatible with maternal and neonatal plasma, RhD
negative (or RhD identical with neonate)”
• “Negative for any red cell antigens to which the mother has antibodies”
• “IAT-cross-match compatible with maternal plasma”
• “5 days old or less (to ensure optimal red cell function and low supernatant
potassium levels)”
• “Collected into CPD anticoagulant and CMV seronegative”
• “Irradiated and transfused within 24 h of irradiation. Irradiation is essential if
the infant has had a previous IUT and is recommended for all ETs”
• “Hematocrit of 0.50–0.60”
• “Not to be transfused straight from 4°C storage. Care should be taken to avoid
over-heating of the component”
Fresh frozen plasma (FFP)—The RBCs are suspended in AB plasma in order to
provide plasma proteins, coagulation factors, and albumin [113]. Reconstituted
whole blood is prepared by adding appropriate amount of FFP into the RBC unit
which is preservative-free. The hematocrit of the unit should be 40–45% [119].
Volume of blood for exchange is calculated using an estimate of the neonate’s
circulating blood volume [113]:
• Term infants: 80–160 mL/kg
• Preterm infants: 100–200 mL/kg
Volume to be exchange ¼ 2 circulating blood volume
The volume to be given is calculated below [119]:
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Total volume in mLð Þ ¼ infant’s weight in kg 85 ∗mL=kg 2
Absolute volume of RBCs required in mLð Þ ¼ total volume 0:45 desired hematocritð Þ
Actual volume of RBCs required in mLð Þ ¼
Absolute volume
Hematocrit of unit after any manipulation
Necessary volume of FFP ¼ total volume required actual volume of RBCs required
ð85–100 mL=kg; depending on estimated blood volumeÞ
6.10.2 Phototherapy
Phototherapy has been proven to be effective in treatment of hyperbilir-
ubinemia by denaturing the bilirubin at appropriate wavelength [28]. AAP and
NICE have laid down guidelines for initiation of treatment, considering gestational
age, birth weight, and cause of hyperbilirubinemia [117, 120].
6.10.3 Intravenous immunoglobulin
IVIG blocks the Fc receptor sites on the cells of the reticuloendothelial system,
thus preventing the hemolysis of sensitized cells. It is mostly used for ABO HDFN
and is not very effective in anti-D-mediated HDFN [25, 28].
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